PL2470545T3 - Bezwodne postaci pochodnej pirydyny - Google Patents

Bezwodne postaci pochodnej pirydyny

Info

Publication number
PL2470545T3
PL2470545T3 PL10747619T PL10747619T PL2470545T3 PL 2470545 T3 PL2470545 T3 PL 2470545T3 PL 10747619 T PL10747619 T PL 10747619T PL 10747619 T PL10747619 T PL 10747619T PL 2470545 T3 PL2470545 T3 PL 2470545T3
Authority
PL
Poland
Prior art keywords
pyridine derivative
anhydrate forms
anhydrate
forms
pyridine
Prior art date
Application number
PL10747619T
Other languages
English (en)
Polish (pl)
Inventor
Andrew Simon Craig
Salima Zarah Ismail
Ronnie Maxwell Lawrence
Original Assignee
Nerre Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerre Therapeutics Ltd filed Critical Nerre Therapeutics Ltd
Publication of PL2470545T3 publication Critical patent/PL2470545T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL10747619T 2009-08-27 2010-08-25 Bezwodne postaci pochodnej pirydyny PL2470545T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23743509P 2009-08-27 2009-08-27
PCT/EP2010/062420 WO2011023733A1 (en) 2009-08-27 2010-08-25 Anhydrate forms of a pyridine derivative
EP10747619.4A EP2470545B1 (en) 2009-08-27 2010-08-25 Anhydrate forms of a pyridine derivative

Publications (1)

Publication Number Publication Date
PL2470545T3 true PL2470545T3 (pl) 2014-03-31

Family

ID=42790943

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10747619T PL2470545T3 (pl) 2009-08-27 2010-08-25 Bezwodne postaci pochodnej pirydyny

Country Status (18)

Country Link
US (1) US8796269B2 (en0)
EP (1) EP2470545B1 (en0)
JP (3) JP2013503134A (en0)
KR (1) KR20120056258A (en0)
CN (1) CN102639536B (en0)
AU (1) AU2010288502B2 (en0)
BR (1) BR112012003435A2 (en0)
CA (1) CA2772168C (en0)
DK (1) DK2470545T3 (en0)
EA (1) EA021411B1 (en0)
ES (1) ES2440938T3 (en0)
IL (1) IL217922A (en0)
IN (1) IN2012DN01292A (en0)
MX (1) MX2012002369A (en0)
PL (1) PL2470545T3 (en0)
SG (1) SG178231A1 (en0)
WO (1) WO2011023733A1 (en0)
ZA (1) ZA201200812B (en0)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120056258A (ko) * 2009-08-27 2012-06-01 글락소스미스클라인 엘엘씨 피리딘 유도체의 무수물 형태
US10314835B2 (en) 2014-06-25 2019-06-11 Emory University Methods of managing conditioned fear with neurokinin receptor antagonists
CN114306335A (zh) 2015-05-18 2022-04-12 康堤医疗有限公司 用于治疗性激素依赖性疾病的双重nk-1/nk-3受体拮抗剂
JP7110197B2 (ja) * 2016-12-15 2022-08-01 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Nrf2アクチベーター
MY201590A (en) * 2018-03-14 2024-03-04 Kandy Therapeutics Ltd Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists
WO2021030335A1 (en) * 2019-08-12 2021-02-18 Millendo Therapeutics, Inc. A stereoisomerically pure nk-3 receptor antagonist and crystalline forms thereof
KR20220101090A (ko) 2019-11-15 2022-07-19 칸디 테라퓨틱스 리미티드 Nt-814의 핵심 중간체인 6-클로로-4-(4-플루오로-2-메틸페닐)피리딘-3-아민의 새로운 화학적 제조 방법
EP4431512A1 (en) 2023-03-16 2024-09-18 Bayer Consumer Care AG Novel dual nk-1/nk-3 receptor antagonists
WO2025242585A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant
WO2025242584A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag A stable soft gelatin capsule formulation for elinzanetant
WO2025242583A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Novel formulation comprising elinzanetant in a solid dispersion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1394150E (pt) * 1999-02-24 2011-02-17 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilização como antagonistas dos receptores de nc-1
GB0203022D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
MXPA05008171A (es) * 2003-01-31 2005-10-05 Hoffmann La Roche Nueva forma cristalina de la 2-(3, 5-bis- trifluormetil -fenil) -n-[6- (1, 1-dioxo -1 lambda 6- tiomorfolin -4-il)- 4-(4-fluor -2-metil -fenil)- piridin-3 -il]-n -metil- isobutiramida.
DK1643998T3 (da) * 2003-07-03 2007-12-27 Hoffmann La Roche NK1/NK3-antagonister til behandling af skizofreni
CA2621564C (en) * 2005-09-09 2014-06-03 Smithkline Beecham Corporation Pyridine derivatives and their use in the treatment of psychotic disorders
KR20100101051A (ko) * 2007-12-11 2010-09-16 씨아이피엘에이 엘티디. 조피클론 결정성 다형체, 이들의 제조 공정 및 이들의 약제 조성물
GB0814340D0 (en) * 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
KR20120056258A (ko) * 2009-08-27 2012-06-01 글락소스미스클라인 엘엘씨 피리딘 유도체의 무수물 형태
JP6342662B2 (ja) * 2014-01-29 2018-06-13 京セラ株式会社 ドリルおよびそれを用いた切削加工物の製造方法

Also Published As

Publication number Publication date
JP2016000739A (ja) 2016-01-07
SG178231A1 (en) 2012-03-29
JP6404186B2 (ja) 2018-10-10
IL217922A0 (en) 2012-03-29
US20120157450A1 (en) 2012-06-21
DK2470545T3 (da) 2014-01-13
EA021411B1 (ru) 2015-06-30
CA2772168C (en) 2019-01-08
ES2440938T3 (es) 2014-01-31
CN102639536A (zh) 2012-08-15
EP2470545B1 (en) 2013-10-09
JP2017193564A (ja) 2017-10-26
KR20120056258A (ko) 2012-06-01
WO2011023733A1 (en) 2011-03-03
CA2772168A1 (en) 2011-03-03
MX2012002369A (es) 2012-03-29
BR112012003435A2 (pt) 2016-02-23
IL217922A (en) 2016-06-30
JP2013503134A (ja) 2013-01-31
EP2470545A1 (en) 2012-07-04
CN102639536B (zh) 2015-03-18
IN2012DN01292A (en0) 2015-06-05
ZA201200812B (en) 2013-03-27
AU2010288502A1 (en) 2012-02-23
EA201270302A1 (ru) 2012-07-30
US8796269B2 (en) 2014-08-05
AU2010288502B2 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
IL217922A0 (en) Anhydrate forms of a pyridine derivative
ZA201105479B (en) Pyridine derivative
EP2412708A4 (en) SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE
EP2514747A4 (en) SUBSTITUTED AMINOTHIAZINE DERIVATIVE
IL220616A0 (en) Novel 3 - hydroxy - 5 - arylisothiazole derivative
EP2420493A4 (en) HALOALKYLSULFONANILIDE DERIVATIVES
EP2495238A4 (en) NEW 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE
IL235745A (en) Annotated 2-Aminopyridine
GB0914661D0 (en) System for derermination of downhole position
PL2433940T3 (pl) Pochodna spiroimidazolonu
PL2444395T3 (pl) Podstawiona pochodna izochinoliny
PL2397480T3 (pl) Pochodna diazepinodionu
LT2155200T (lt) Karbamoil-cikloheksano darinio kristalinė forma
AP3169A (en) A method of improved positioning
IL213466A0 (en) Spiroindolinone pyridine derivative
ZA201204063B (en) 2-pyridone compounds
ZA201202899B (en) 5-hydroxypyrimidine-4-carboxamide derivative
ZA201105014B (en) Dihydroquinolinone derivatives
ZA201107617B (en) Carbinol compound having heterocyclic linker
GB0918358D0 (en) Wellbore completion
IL210777A0 (en) Crystalline forms of a pyridine derivative
GB0918922D0 (en) Aminopyridine derivatives
IL214028A0 (en) A novel cyanopyrimidine derivative
EP2476682A4 (en) 8-oxodihydropurine DERIVATIVE
EP2394988A4 (en) SUBSTITUTED ACYLGUANIDINE DERIVATIVE